Advertisement

September 8, 2020

FDA Approves IDE for CARENET-III Pivotal Trial of InspireMD’s CGuard Carotid Stent System

September 8, 2020—InspireMD, Inc., the Israel-based developer of the CGuard embolic prevention system for the prevention of stroke caused by carotid artery disease, announced FDA approval for the company to proceed with the CARENET-III pivotal study of the CGuard carotid stent system for prevention of stroke in patients in the United States.

The company advised that the CARENET-III study would be composed of 315 patients enrolled at up to 40 institutions in the United States. The company will provide additional details as plans advance.

Advertisement


September 8, 2020

Sirtex Medical Makes a Strategic Investment in Nanospectra Biosciences

September 8, 2020

SCAI Membership Survey Addresses Treatment of CLI